SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Royal Caribbean Cruises Ltd. – RCL

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Royal Caribbean Cruises Ltd. (“Royal Caribbean” or the “Company”) (NYSE: RCL). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether Royal Caribbean and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 



[Click here for information about joining the class action]

On February 13, 2020, Royal Caribbean issued a press release stating that it had canceled 18 voyages in Southeast Asia due to recent travel restrictions and further warning that recent bookings had been softer for its broader business. On February 25, 2020, Royal Caribbean filed its 2019 Form 10-K, indicating that COVID-19 concerns were negatively impacting its overall business. 

On March 10, 2020, Royal Caribbean withdrew its 2020 financial guidance, increased its revolving credit facility by $550 million, and announced that it would take cost-cutting actions due to the proliferation of COVID-19, further revealing that COVID-19 was severely impacting Royal Caribbean’s 2020 customer booking and that its safety measures were inadequate to prevent the spread of the virus on its ships. 

On March 11, 2020, Royal Caribbean’s largest competitor, Carnival, announced a 60-day suspension of all operations, prompting concern that Royal Caribbean would follow suit. At the same time, Royal Caribbean also cancelled two cruises, beginning a series of cancellations and suspensions to follow. 

On March 14, 2020, Royal Caribbean announced a suspension of all global cruises for 30 days. 

On March 16, 2020, the Company revealed that global operations could be suspended longer than anticipated, announcing the cancellations of two additional cruises throughout April and into May. 

Finally, on March 18, 2020, analysts downgraded Royal Caribbean’s stock and slashed their price targets. 

Following each of the foregoing disclosures, Royal Caribbean’s stock price fell sharply, damaging investors.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Evolus, Inc. of Class Action Lawsuit and Upcoming Deadline – EOLS

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Evolus, Inc. (“Evolus” or the “Company”) (NASDAQ: EOLS). The class action, filed in United States District Court for the Southern District of New York, and docketed under 20-cv-09053, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquired Evolus securities between February 1, 2019 and July 6, 2020, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violation of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are a shareholder who purchased Evolus securities during the class period, you have until December 15, 2020, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 



[Click here for information about joining the class action]

Evolus is a Delaware corporation headquartered in Newport Beach, California. The Company operates as a medical aesthetics company, and develops, produces, and markets clinical neurotoxins for the treatment of aesthetic concerns. Evolus’ sole product is Jeuveau™, which is a purified botulinum toxin indicated for the temporary improvement in the appearance of moderate to severe frown lines in adults. As such, Evolus directly competes with Botox®, which is manufactured by Allergan plc and Allergan Inc. (“Allergan”) and distributed by Medytox Inc. (“Medytox”). Botox® has been the gold standard of the industry since its approval by the U.S. Food and Drug Administration (“FDA”) more than two decades ago.

Beginning in February 2019, Evolus embarked on a public campaign to hype the market right before the commercial launch of its sole leading product Jeuveau™. To secure an aggressive growth and rapid influx of revenue, Defendants disseminated dozens of public statements in which they promoted Jeuveau™ as a proprietary formulation of the botulinum toxic type A complex, purportedly developed by Korean bioengineering company Daewoong through years of clinical research and millions of dollars’ worth of investment in research and development. Among other things, Evolus promised investors that it would attain the number two U.S. market position within twenty-four months of launch.

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading because they misrepresented and failed to disclose the following adverse facts pertaining to the Company’s business, operations, and prospects, which were known to Defendants or recklessly disregarded by them. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the real source of botulinum toxin bacterial strain as well as the manufacturing processes used to develop Jeuveau™ originated with and were misappropriated from Medytox; (ii) sufficient evidentiary support existed for the allegations that Evolus misappropriated certain trade secrets relating to the botulin toxin strain and the manufacturing processes for the development of Jeuveau™; (iii) as a result, Evolus faced a real threat of regulatory and/or court action, prohibiting the import, marketing, and sale of Jeuveau™; which in turn (iv) seriously threatened Evolus’ ability to commercialize Jeuveau™ in the U.S. and generate revenue; and (v) any revenues generated from the sale of Jeuveau™ were based on Evolus’ unlawful activities, including the misappropriation of trade secrets and secret manufacturing processes belonging to Allergan and Medytox.

The investing public learned the truth about Jeuveau™ on July 6, 2020, when the U.S. International Trade Commission (“ITC”) issued its Initial Final Determination in a case brought by Allergan and Medytox against Evolus, alleging that Evolus stole certain trade secrets to develop Jeuveau™. Coming as a great surprise to unsuspecting investors, the ITC Judge found that Evolus misappropriated the botulinum toxin strain as well as the manufacturing processes that led to its development and manufacture. Additionally, the ITC Judge recommended a ten-year-long ban on Evolus’ ability to import Jeuveau™ into the U.S. and a ten-year-long cease-and-desist order preventing Evolus from selling Jeuveau™ in the U.S.

This news caused a precipitous and immediate decline in the price of Evolus shares, which fell 37% over the course of two trading days, to close at $3.35 per share on July 8, 2020, on unusually high trading volume. Following the news of the ITC’s Initial Final Determination and the subsequent price drop of Evolus’ common shares, several securities analysts downgraded Evolus’ rating and significantly lowered the Company’s price target.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980

Bango and Microsoft sign agreement to boost new Xbox cloud gaming subscriptions

  • Opening-up access to Xbox consoles and games through the Bango Platform

CAMBRIDGE, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) — Bango (AIM: BGO) (“Bango”), the global platform for data-driven commerce, has expanded its partnership with Microsoft (NASDAQ: MSFT) to open-up access to Xbox subscriptions and consoles sales. With new Xbox Series X and Xbox Series S now available in time for the year end buying season, the Xbox Game Pass Ultimate subscription service and Xbox All Access program are expected to be in high demand.

Microsoft will leverage the Bango Platform to enable telco partners to bundle Xbox Game Pass Ultimate and Xbox All Access in their subscription packages. This is the latest expansion of the Bango partnership with Microsoft, through which Bango powers carrier billed payments for Xbox gamers and across the Microsoft Store.

Xbox Game Pass Ultimate gives gamers access to over 100 high-quality games on console, PC and compatible mobile devices for one low monthly price.

With Xbox All Access players can get everything they need to jump into the next generation of gaming – an Xbox Series X or Xbox Series S, plus 24 months of Xbox Game Pass Ultimate – from $24.99 a month for 24 months with no upfront cost.

Partners that want to benefit from the global demand for Xbox gaming can now leverage the unique offer and targeting insights provided by the Bango Platform to attract many more customers.

Gaming subscriptions and console acquisition programs are aligned to the way consumers are increasingly accessing entertainment. Consumers are standardizing on cloud gaming subscription services for gaming content as it dramatically increases choice, compared to pay per game business models.


Bango
is
focus
ed
on growing success for partners through data driven commerce
.
Unique
Bango
data insights optimize the targeting of product
bun
dl
es
to boost consumer engagement.
Bango is excited to expand
its
partnership with Microsoft
,
to
tak
e
Xbox
Game Pass
and consoles
to
millions
more
gamers
across the world,

commented
Paul Larbey, CEO
at Bango.

About Bango

App developers, stores and payment providers cross the threshold into the Bango ecosystem to converge, grow and thrive. By bringing businesses together and powering e-commerce with unique data-driven insights, Bango delivers new business opportunities and new dimensions of growth for customers around the world. Being inside the Bango circle means global merchants including Amazon, Google and Microsoft can work together with payment partners from Africa to the Americas, accelerating the performance of everyone on the inside.

Bango. Think inside the circle. For more information, visit www.bango.com.

Media contact:

Anil Malhotra, CMO
[email protected]
Tel: +44 7710 480 377

Skanska signs additional contracts for office improvements in western USA for about USD 198 M, about SEK 1.7 billion

PR Newswire

ÖSTERSUND, Sweden, Nov. 12, 2020 /PRNewswire/ — Skanska has signed additional contracts with an existing client for improvements to their corporate office in the western USA. The contract is a joint venture with Skanska Balfour Beatty, and is worth USD 395 M. Skanska’s part is worth about USD 198 M, about SEK 1.7 billion, which will be included in the US order bookings for the fourth quarter of 2020.

Construction is underway and is scheduled for completion in the fourth quarter of 2023.

Skanska is one of the leading construction- and development companies in USA, specializing in building construction, civil infrastructure and developing commercial properties in select U.S. markets. Skanska USA had sales of SEK 74 billion and about 7,900 employees in its operations in 2019.

CONTACT:

For further information please contact:

Yena Williams

Communications Director, Skanska USA
tel +1-213-514-2918

Olof Rundgren

Media Relations Manager, Skanska AB
tel +46 (0)10-448-67-94

Direct line for media, tel +46 (0)10-448-88-99

This and previous releases can also be found at

www.skanska.com
.

 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/skanska/r/skanska-signs-additional-contracts-for-office-improvements-in-western-usa-for-about-usd-198-m–about,c3235529

The following files are available for download:


https://mb.cision.com/Main/95/3235529/1333884.pdf

20201112 US office improvements

 

Cision View original content:http://www.prnewswire.com/news-releases/skanska-signs-additional-contracts-for-office-improvements-in-western-usa-for-about-usd-198-m-about-sek-1-7-billion-301171604.html

SOURCE Skanska

Equinor ASA: Ex dividend

From 12 November 2020, the shares in Equinor (OSE: EQNR, NYSE: EQNR) will be traded ex dividend at USD 0.09.

Record date is 13 November 2020.

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Borr Drilling Limited – SGM Results Notification

PR Newswire

HAMILTON, Bermuda, Nov. 12, 2020 /PRNewswire/ — Borr Drilling Limited (the “Company”) (NYSE: “BORR”, OSE: “BDRILL”) advises that a Special General Meeting of the Company was held on November 11, 2020 at 09:30 AST at 2nd Floor, The S.E. Pearman Building, 9 Par-la-Ville Road, Hamilton HM 11, Bermuda

The following resolution was passed:

To approve the increase of the Company’s authorized share capital from US$11,182,692.30 divided into 223,653,846 common shares of US$0.05 par value each to US$11,932,692.30 divided into 238,653,846 common shares of US$0.05 par value each by the authorization of an additional 15,000,000 common shares of US$0.05 par value each.

Media Contact:

Magnus Vaaler

VP Investor Relations and Treasury
+47-22-48-30-00

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/borr-drilling-limited/r/borr-drilling-limited—sgm-results-notification,c3235657

 

Cision View original content:http://www.prnewswire.com/news-releases/borr-drilling-limited–sgm-results-notification-301171590.html

SOURCE Borr Drilling Limited

Nel ASA: Reference is made to stock exchange announcement regarding contract for multiple hydrogen fueling stations

PR Newswire

OSLO, Norway, Nov. 12, 2020 /PRNewswire/ — On 30 June 2020 Nel Hydrogen Fueling, a division of Nel ASA (Nel, OSE:NEL), received a purchase order for multiple H2Station™ units for fueling of light-duty vehicles in California from Iwatani Corporation of America, a wholly owned subsidiary of Iwatani Corporation (8088: Tokyo Stock Exchange).

“We are very honored that Iwatani and Toyota have selected our H2Station™ hydrogen fueling station solutions for strengthening the hydrogen infrastructure in Southern California. The stations will serve existing as well as new fuel cell electric vehicles, such as the next generation Toyota Mirai, with zero-emission fuel, at the same convenience as conventional fuels. With our Nel Inc. entity currently based in the San Francisco area we now look forward to expanding our business in California and supporting Iwatani,” says Ulrik Torp Svendsen, Key Account Manager, Nel Hydrogen Fueling.

The value of the purchase order was in excess of NOK 150 million, and included 14 H2Station™ modules which will be installed in 2021 on 7 sites in California, US for fueling of passenger vehicles.

Link to press-release from Iwatani and Toyota: https://pressroom.toyota.com/iwatani-corporation-of-america-and-toyota-collaborate-to-bring-seven-new-hydrogen-refueling-stations-to-southern-california/

For further information, please contact:

Jon André Løkke
CEO, +47-907-44-949

Bjørn Simonsen
VP Investor Relations & Corporate Communication
+47-971-79 821

About Nel ASA | www.nelhydrogen.com

Nel is a global, dedicated hydrogen company, delivering optimal solutions to produce, store, and distribute hydrogen from renewable energy. We serve industries, energy, and gas companies with leading hydrogen technology. Our roots date back to 1927, and since then, we have had a proud history of development and continuous improvement of hydrogen technologies. Today, our solutions cover the entire value chain: from hydrogen production technologies to hydrogen fueling stations, enabling industries to transition to green hydrogen, and providing fuel cell electric vehicles with the same fast fueling and long range as fossil-fueled vehicles – without the emissions.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nel-asa/r/nel-asa–reference-is-made-to-stock-exchange-announcement-regarding-contract-for-multiple-hydrogen-f,c3235775

The following files are available for download:

 

 

Cision View original content:http://www.prnewswire.com/news-releases/nel-asa-reference-is-made-to-stock-exchange-announcement-regarding-contract-for-multiple-hydrogen-fueling-stations-301171588.html

SOURCE NEL ASA

Interim Report Q3, 2020

Expansion of pipeline and positive phase 3 topline data

PR Newswire

STOCKHOLM, Nov. 12, 2020 /PRNewswire/ — “On August 13th, we announced a €19.8m acquisition of a majority stake of 62.7% in Genkyotex, a publicly listed life science company in France. We are very excited about this acquisition, which complements our existing and long-standing focus on inflammatory disease. This provides us with a platform with anti-fibrotic and anti-inflammatory compounds, with which we believe can continue to address unmet medical need in orphan diseases and bring solutions to patients across many different therapeutic areas. We believe that we have significant opportunities to leverage this platform to the benefit of patients suffering from fibrotic diseases. We believe that the late stage development, CMC and regulatory expertise which exists in Calliditas can significantly support and enhance the important fundamentals put in place by Genkyotex. We are confident that this will be value driving, for all the company’s stakeholders, over the near and medium term.

After the close of the quarter, on November 8th, we reported positive topline results from Part A of our pivotal Phase 3 trial, NefIgArd. The strong data set confirms the results seen in the successful Phase 2b trial and provides further support for locally treating IgAN at the source, offering patients hope of disease modification. We will now assemble the regulatory file and submit for accelerated approval with the FDA and conditional approval with EMA, which is planned for Q1 and H1 respectively next year.”

Renée Aguiar-Lucander, CEO

Summary of Q3 2020

July 1 – September 30, 2020

  • No net sales were recognized for the three months ended September 30, 2020 and 2019, respectively.
  • Operating loss amounted to SEK 104.9 million and SEK 52.6 million for the three months ended September 30, 2020 and 2019, respectively.
  • Loss before income tax amounted to SEK 137.9 million and SEK 50.1 million for the three months ended September 30, 2020 and 2019, respectively.
  • Loss per share before and after dilution amounted to SEK 2.77 and SEK 1.30, for the three months ended September 30, 2020 and 2019, respectively.
  • Cash amounted to SEK 1,396.9 million and SEK 805.1 million as of September 30, 2020 and 2019, respectively.

Significant events during Q3 2020, in summary

  • In July 2020, Calliditas announced the exercise of the partial over-allotment option from the IPO on The Nasdaq Global Select Market. Calliditas was thereby provided with additional gross proceeds of approximately USD 6.9 million (approximately SEK 63 million) before deduction of issuance costs.
  • In August 2020, Calliditas announced it has reached an agreement to acquire a controlling interest in Genkyotex SA, a leader in NOX inhibition therapies.

Significant events after the end of reporting period, in summary

  • In November 2020, Calliditas acquired a controlling interest in Genkyotex SA representing 62,7%.
  • In November 2020, Calliditas announced positive topline results from Part A from the pivotal Phase 3 NefIgArd trial.

Investor Presentation November 12, 14:30 CET

Audio cast with teleconference, Q3 2020, November 12, 2020, 14:30 (Europe/Stockholm)

Webcast: https://tv.streamfabriken.com/calliditas-therapeutics-q3-2020  

Teleconference: SE: +46856642707 UK: +443333009034 US: +18332498405

Financial calendar

Year-end report for the period January 1 – December 31, 2020  February 18, 2021

Interim report for the period January 1 – March 31, 2021  May 13, 2021

Interim report for the period January 1 – June 30, 2021  August 19, 2021

Interim report for the period January 1 – September 30, 2021  November 18, 2021

For further information, please contact:

Renée Aguiar-Lucander, CEO at Calliditas
Email: [email protected]

Mikael Widell, Investor Relations
Email: [email protected]
Telephone: +46 703 11 99 60

The information in the press release is information that Calliditas is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 07:00 CET on November 12, 2020.

About Calliditas Therapeutics

Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the Company can partially or completely participate in the commercialization efforts. The Company is focused on the development and commercialization of the product candidate Nefecon, a unique two-step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas Therapeutics is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the US. The company is listed on Nasdaq Stockholm (ticker: CALTX). Visit www.calliditas.com  for further information.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Calliditas’ strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Calliditas” business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other biopharmaceutical companies, and other risks identified in the section entitled “Risk Factors” Calliditas’ reports filed with the Securities and Exchange Commission. Calliditas cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Calliditas disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Calliditas” views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/calliditas-therapeutics/r/interim-report-q3–2020,c3235709

The following files are available for download:

 

Cision View original content:http://www.prnewswire.com/news-releases/interim-report-q3-2020-301171586.html

SOURCE Calliditas Therapeutics

Targa Telematics Awards TomTom Multiyear Contract

TomTom Maps APIs to enhance Targa Telematics’ vehicle management and smart mobility solutions

AMSTERDAM, The Netherlands, Nov. 12, 2020 (GLOBE NEWSWIRE) — TomTom (TOM2), the location technology specialist, and Targa Telematics, an IT company boasting 20-years of experience in connected vehicles, today announced a new multiyear agreement. TomTom’s Maps APIs will be used by Targa Telematics to enhance the vehicle management and smart mobility solutions offered to its customers.

TomTom’s Search API, which companies rely on to understand where their fleets are located, will be integrated in Targa Telematics’ wide and advanced telematics, telemetry and smart mobility solution portfolio. TomTom’s Routing API will enable Targa Telematics customers to perform trip analyses and find the best routes.

“Leading players in fleet management and smart mobility services, such as Targa Telematics, greatly benefit from TomTom’s range of Maps APIs and dependable customer support,” said Anders Truelsen, Managing Director, TomTom Enterprise. “We are proud that TomTom is rapidly becoming the location technology supplier of choice for the fleet industry.”

“Targa Telematics has always been at the forefront in supporting businesses to meet the consistently growing need of a more sustainable and secure approach to mobility. Given this evolving scenario, we want to continue on this path,” commented Giorgia Paladin, Head of Procurement at Targa Telematics. “Through this deal with TomTom, our customers will continue benefiting from innovative solutions with outstanding coverage across Europe.”

Targa Telematics has been a pioneer of smart mobility since its foundation. Thanks to its innovative technology, Targa Telematics helps its customers to embrace connectivity, the switch to electric vehicles, and supports the sustainable development of cities. By leveraging its vast knowledge and Internet of Things platform, Targa Telematics continues to develop solutions that meet its clients’ evolving needs.

About TomTom:

TomTom is the leading independent location technology specialist, shaping mobility with highly accurate maps, navigation software, real-time traffic information and services.

To achieve our vision of a safer world, free of congestion and emissions, we create innovative technologies that keep the world moving. By combining our extensive experience with leading business and technology partners, we power connected vehicles, smart mobility and, ultimately, autonomous driving.

Headquartered in Amsterdam with offices in 30 countries, TomTom’s technologies are trusted by hundreds of millions of people worldwide.

www.tomtom.com

For further Information:

Media:

[email protected]

Investor Relations:
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2d659126-fb2b-43c0-8540-e74493bd09d0

Wix Reports Third Quarter 2020 Results

– Outperformance continues in Q3 with strong revenue and collections growth, well ahead of expectations

— Revenue of $254.2 million, up 29% y/y

— Collections of $280.9 million, up 36% y/y, an acceleration from Q2 y/y growth

— Creative Subscriptions ARR increased 24% y/y to $840.5 million

– Rising value of user cohorts driven by large Q3 cohort of 7.8 million new users and continued momentum from Q1 and Q2 2020 user cohorts

— Q3 user cohort generated highest conversion of registered users to premium subscriptions in over two years as well as higher collections per subscription

— Future collections expected from existing cohorts increased 43% versus a year ago to over $9.2 billion over the next 8 years

– Businesses continue to turn to Wix to build and manage their online presence

— Growing adoption of Business package subscriptions, business applications and Wix Payments throughout Q3

— Strong growth in Wix Stores subscriptions in Q3, increasing over 2x overall subscriptions

– Record levels of demand and strong execution in 2020 paves the way for multiple growth drivers in 2021 and beyond

PR Newswire

NEW YORK, Nov. 12, 2020 /PRNewswire/ — Wix.com Ltd. (Nasdaq: WIX) today reported strong financial results for the third quarter ended September 30, 2020, exceeding the high end of its guidance ranges for revenue, collections and free cash flow. In addition, the Company provided its outlook for the fourth quarter of 2020.

“Demand for an online presence continues to remain at high levels,” said Avishai Abrahami, Co-founder and CEO of Wix. “Businesses are using Wix more than ever before, and we are seeing them utilize our platform to not only help them create a website, but also to support them as they manage their business and grow their brands. Our web creation products and business solutions have enabled millions of our users to achieve success despite the ongoing difficulties that they are facing.”

Lior Shemesh, CFO of Wix, added, “Our strong results in Q3 were driven by continued high levels of demand from new users for our website creation products and business solutions as well as the ongoing monetization of users who joined Wix over the most recent quarters. Users that joined Wix during Q3 purchased subscriptions at higher rates that we have seen in several years and at higher prices. This significant growth in new users, as well as our continued execution in product development and marketing, position us well to drive growth in 2021 and beyond.”

Nir Zohar, President and COO, said, “Throughout Q3, even as parts of the world began re-opening economies, we experienced strong growth, which demonstrates the new state of mind for people and businesses about the need for an online presence. Our teams across the globe continue to execute at their highest levels throughout this tumultuous time, providing world class solutions for those in need of an online presence. We remain focused on meeting the needs of users who come to Wix to create, manage and grow their businesses and brands online.”


Q3 2020 Financial Results


  • Total revenue in the third quarter of 2020 was $254.2 million, compared to $196.8 million in the third quarter of 2019, an increase of 29% y/y
    • Creative Subscriptions revenue in the third quarter of 2020 was $203.0 million, compared to $164.8 million in the third quarter of 2019, an increase of 23% y/y
    • Business Solutions revenue in the third quarter of 2020 was $51.2 million, compared to $32.0 million in the third quarter of 2019, an increase of 60% y/y
  • Creative Subscriptions ARR was $840.5 million in the third quarter of 2020, compared to $680.4 million in the third quarter of 2019, an increase of 24% y/y
  • Total collections in the third quarter of 2020 were $280.9 million, compared to $205.9 million in the third quarter of 2019, an increase of 36% y/y
    • Creative Subscriptions collections in the third quarter of 2020 were $228.3 million, compared to $173.6 million in the third quarter of 2019, an increase of 32% y/y
    • Business Solutions collections in the third quarter of 2020 were $52.6 million, compared to $32.3 million in the third quarter of 2019, an increase of 63% y/y
  • Total gross margin on a GAAP basis in the third quarter of 2020 was 69%, compared to 73% in the third quarter of 2019. The y/y decline was related to incremental investments in Customer Care, hosting and the faster revenue growth of the Business Solutions segment
    • Creative Subscriptions gross margin on a GAAP basis was 79%, compared to 81% in the third quarter of 2019. The y/y decline was related to the investment in expanding our Customer Care organization and higher hosting costs to serve the increased number of users
    • Business Solutions gross margin on a GAAP basis was 29% compared to 32% in the third quarter of 2019. The y/y decline was related primarily to the growth of Wix Payments, the expansion of Customer Care and higher hosting costs to meet the increased number of users
  • Total non-GAAP gross margin in the third quarter of 2020, calculated as non-GAAP gross profit as a percent of revenue, was 70%, compared to 74% in the third quarter of 2019. The y/y decline was related to incremental investments in Customer Care, hosting and the faster revenue growth of the Business Solutions segment
    • Creative Subscriptions gross margin on a non-GAAP basis was 80%, compared to 82% in the third quarter of 2019. The y/y decline was related to the investment in expanding our Customer Care organization and higher hosting costs to serve the increased number of users
    • Business Solutions gross margin on a non-GAAP basis was 31%, compared to 33% in the third quarter of 2019. The y/y decline was related primarily to the growth of Wix Payments, the expansion of Customer Care and higher hosting costs to meet the increased number of users
  • GAAP net loss in the third quarter of 2020 was $(56.8) million, or $(1.03) per share, compared to a net loss of $(17.4) million, or $(0.34) per share, for the third quarter of 2019
  • Non-GAAP net loss in the third quarter of 2020 was $(8.0) million, or $(0.14) per share, compared to non-GAAP net income of $20.8 million, or $0.41 per share, for the third quarter of 2019
  • Net cash provided by operating activities in the third quarter of 2020 was $24.5 million, while capital expenditures totaled $5.1 million, leading to free cash flow of $19.4 million, compared to $29.2 million of free cash flow in the third quarter of 2019, a (34)% y/y decrease
    • Excluding the capex investment associated with our new headquarters office build out, free cash flow would have been $20.2 million, a decrease of (31)% y/y
  • Added 302,000 net premium subscriptions in the third quarter of 2020, a 164% increase y/y, to reach 5.3 million as of September 30, 2020, a 20% increase over the total number of premium subscriptions at the end of the third quarter of 2019
  • Added 7.8 million registered users in the third quarter of 2020, a 42% increase y/y. Registered users as of September 30, 2020 were 189 million, representing a 19% increase compared to the end of the third quarter of 2019


Recent Business Highlights

  • In August, Wix issued $575 million of 0% convertible senior notes due 2025. The size of the offering was upsized from the initial base offering and includes the over-allotment option that the initial purchasers exercised in full. In connection with this offering, Wix entered into negotiated capped call transactions that are expected generally to reduce the potential dilution to the ordinary shares of Wix upon any conversion of Notes and/or to offset any cash payments Wix is required to make in excess of the principal amount of converted Notes, as the case may be, with such reduction and/or offset subject to a cap. Proceeds from the offering were partially used to pay for the capped call transactions with the remaining net proceeds to be used for potential acquisitions or general corporate purposes
  • Announced Wix Capital, an internal venture arm that invests in technology innovators that are focused on the future of the web and that look to accelerate how businesses operate in today’s evolving digital landscape
  • Partnered with Vodafone to bring Wix to the Vodafone Business Marketplace platform, enabling its customers to build an online presence. The Vodafone partnership was a key milestone for the Wix Channels initiative, which expands Wix’s global growth by enabling international service providers to sell Wix website subscriptions and business solutions directly to their customers
  • Announced the expansion of the Wix Playground Academy, an intensive web design program, into Europe in January 2021. The Academy bridges the gap between design school and the professional world and helps designers elevate their multidisciplinary design experience
  • Enabled merchants to offer their buyers installment payment plans for purchases. Wix now offers Afterpay in the US, Australia and New Zealand and Clearpay in the UK as well as Laybuy in the UK, Australia and New Zealand


Financial Outlook

Despite the continued uncertainty surrounding the pandemic, we remain focused on being a destination for creators and businesses to move and grow online. Our Q4 guidance reflects the new state of mind of creators and businesses about the importance of an online presence and the continuation of demand for our offering.

Our outlook is also underscored by continued gains from investments in our business, including improving and growing our Customer Care organization, bolstering our hosting infrastructure and increasing marketing activities. We believe these investments will continue to drive positive returns.

We are introducing Q4 guidance as follows:

Q4 2020 Outlook

Y/Y growth

Implied FY 2020

Outlook

Y/Y
growth

Revenue

$266 – 271 million

30 – 32%

$972 – 977 million

28%

Collections

$295 – 305 million

30 – 35%

$1,090 – 1,100 million

31 – 32%

Free Cash Flow

$16 – 21 million

(57) – (44)%

$122 – 127 million

(4) – 0%

Free Cash Flow
(excluding capex for future
Wix HQ office build out)

$17 – 22 million

(55) – (41)%

$125 – 130 million

(2) – 2%


Conference Call and Webcast Information

Wix will host a conference call at 8:30 a.m. ET on Thursday, November 12, 2020 to answer questions about the financial and operational performance of the business for the third quarter ended September 30, 2020. The conference call will include a brief statement by management and will focus on answering questions about our results during the quarter. To enhance the Q&A portion of this call, the Company has posted a shareholder update and supporting slides to its Investor Relations website at https://investors.wix.com/. These materials provide shareholders and analysts with additional detail for analyzing results in advance of the quarterly conference call.

To participate on the live call, analysts and investors should dial +1-877-667-0467 (US/ Canada), +1-346- 354-0953 (International) or 1-809-315-362 (Israel) at least ten minutes prior to the start time of the call and reference Conference ID 4409229. A telephonic replay of the call will be available through November 19, 2020 at 11:30 a.m. ET by dialing +1-855-859-2056 and providing Conference ID 4409229.

Wix will also offer a live and archived webcast of the conference call, accessible from the “Investor Relations” section of the Company’s website at https://investors.wix.com/.


About Wix.com Ltd.


Wix
 is leading the way with a cloud-based website development platform for over 189 million registered users worldwide today. The Wix website builder was founded on the belief that the Internet should be accessible to everyone to develop, create and contribute. Through free and premium subscriptions, Wix empowers millions of businesses, organizations, artists, and individuals to take their businesses, brands and workflow online. The Wix Editor, Wix ADI, Editor X, a highly curated App Market, Ascend by Wix and Corvid by Wix enable users to build and manage a fully integrated and dynamic digital presence. Wix’s headquarters are in Tel Aviv with offices in Austin, Be’er Sheva, Berlin, Cedar Rapids, Denver, Dnipro, Dublin, Kiev, Los Angeles, Miami, New York, San Francisco, São Paulo, Tokyo and Vilnius. 

Visit us: on our blog, Facebook, Twitter, Instagram, LinkedInand Pinterest
Download: Wix App is available for free on Google Play and in the App Store 
For more about Wix please visit our Press Room 


Non-GAAP Financial Measures


To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S.  GAAP,  Wix  uses  the  following  non-GAAP  financial   measures:   collections,   cumulative   cohort collections, collections  on  a  constant  currency  basis,  revenue  on  a  constant  currency  basis,  non-GAAP  gross  margin,  non-GAAP  operating  income (loss),  non-GAAP  net   income (loss),  non-GAAP  net  income (loss)  per  share,  free  cash  flow, free cash flow, as adjusted, free cash flow margins, non-GAAP R&D expenses, non-GAAP S&M expenses, non-GAAP G&A expenses, non-GAAP operating expenses, non-GAAP cost of revenue expense, non-GAAP tax expense (collectively the “Non-GAAP financial measures”). Measures presented on a constant currency or FX neutral basis have been adjusted to exclude the effect of y/y changes in foreign currency exchange rate fluctuations. Collections represent  the  total  cash  collected  by  us  from our customers in a given period and is calculated by adding the change in deferred revenues for a particular period to revenues for the same period.  Non-GAAP  gross  margin  represents gross profit calculated in accordance with GAAP as adjusted for the impact of share-based compensation expense, acquisition-related expenses and amortization, divided  by  revenue.  Non-GAAP operating income (loss) represents operating income (loss) calculated in accordance with GAAP as adjusted for the impact of  share-based  compensation  expense,  amortization,  acquisition-related  expenses  and  sales tax expense  accrual. Non-GAAP  net  income (loss) represents  net  loss  calculated  in  accordance  with  GAAP as adjusted for the impact of share-based compensation expense, amortization, sales tax expense accrual, amortization of  debt  discount  and  debt  issuance  costs  and  acquisition-related  expenses  and non-operating foreign exchange expenses (income). Non-GAAP net income (loss) per share represents non-GAAP net income (loss) divided by the weighted average number of shares used in computing GAAP loss per share. Free cash flow represents net cash provided by (used in) operating activities less capital expenditures. Free cash flow, as adjusted, represents free cash flow further adjusted to exclude capital expenditures associated with our new headquarters. Free cash flow margins represent free cash flow divided by revenue. Non-GAAP cost of revenue represents cost of revenue calculated in accordance with GAAP as adjusted for the impact of share-based compensation expense, acquisition-related expenses and amortization. Non-GAAP R&D expenses represent R&D expenses calculated in accordance with GAAP as adjusted for the impact of share-based compensation expense, acquisition-related expenses and amortization. Non-GAAP S&M expenses represent S&M expenses calculated in accordance with GAAP as adjusted for the impact of share-based compensation expense, acquisition-related expenses and amortization. Non-GAAP G&A expenses represent G&A expenses calculated in accordance with GAAP as adjusted for the impact of share-based compensation expense, acquisition-related expenses and amortization. Non-GAAP operating expenses represent operating expenses calculated in accordance with GAAP as adjusted for the impact of share-based compensation expense, acquisition-related expenses and amortization.

The presentation of this financial  information  is  not  intended  to  be considered in isolation or as a substitute for, or superior to, the financial information  prepared  and  presented  in  accordance  with  GAAP.  The  Company uses these non-GAAP financial measures for financial and operational decision  making  and  as  a means to  evaluate  period-to-period  comparisons.  The  Company  believes  that  these  measures  provide  useful information about operating results, enhance  the overall understanding of past financial performance  and  future  prospects,  and  allow  for  greater  transparency with respect to key metrics used by management in its financial and operational decision making.

For more information on the  non-GAAP  financial  measures,  please  see  the reconciliation tables provided below. The accompanying tables have more details on the GAAP financial measures  that  are  most  directly  comparable  to  non-GAAP  financial  measures  and  the  related reconciliations between these financial measures. The Company is unable to provide reconciliations of free cash flow, free cash flow, as adjusted, cumulative cohort collections, non-GAAP gross margin, and non-GAAP tax expense to their most directly comparable GAAP financial measures on a forward-looking basis without unreasonable effort because items that impact those GAAP financial measures are out of the Company’s control and/or cannot be reasonably predicted.  Such information may have a significant, and potentially unpredictable, impact on our future financial results.


Forward-Looking Statements

This document contains forward-looking statements, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements may include projections regarding our future performance, including, but not limited to revenue, collections and free cash flow, and may be identified by words like “anticipate,” “assume,” “believe,” “aim,” “forecast,” “indication,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “outlook,” “future,” “will,” “seek” and similar terms or phrases. The forward-looking statements contained in this document, including the fourth quarter guidance, are based on management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, our ability to grow our user base and premium subscriptions, including through our Wix Partner Program; uncertainty surrounding the duration and severity of COVID-19 and its effects on our business, including changes in consumer dynamics shifting to online and increased GMV on our platform; our ability to create new and higher monetization opportunities from our premium subscriptions; our ability to enter into new markets, and attract new customer segments, and our ability to successfully enter into partnership agreements; our ability to maintain and enhance our brand and reputation; our prediction of the future collections generated by our user cohorts; our share repurchases made pursuant to our share repurchase plan; our ability to manage the growth of our infrastructure effectively; our ability to effectively execute our initiatives to scale and improve our user support function, including through the recent expansion of our Customer Solutions organization by engaging additional agents around the world to provide 24/7 support in nine different languages; the success of our sales efforts; customer acceptance and satisfaction of new products and other challenges inherent in new product development; changes to technologies used in our solutions; or changes in global, national, regional or local economic, business, competitive, market, regulatory and other factors discussed under the heading “Risk Factors” in the Company’s 2019 annual report on Form 20-F filed with the Securities and Exchange Commission on April 2, 2020. Any forward-looking statement made by us in this press release speaks only as of the date hereof. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Investor Relations
:

Maggie O’Donnell


[email protected] 
914-267-7390

Media Relations:


[email protected]

Wix.com Ltd.

CONSOLIDATED STATEMENTS OF OPERATIONS – GAAP

(In thousands, except loss per share data)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2019

2020

2019

2020

(unaudited)

(unaudited)


Revenue

Creative Subscriptions

$         164,761

$              202,996

$       473,137

$       569,711

Business Solutions

32,030

51,184

83,363

136,515

196,791

254,180

556,500

706,226


Cost of Revenue

Creative Subscriptions

31,542

43,361

87,485

117,261

Business Solutions

21,753

36,479

52,187

95,131

53,295

79,840

139,672

212,392

Gross Profit

143,496

174,340

416,828

493,834

Operating expenses:

   Research and development

64,488

84,473

184,157

230,653

   Selling and marketing

75,862

113,092

232,909

328,581

   General and administrative

23,751

26,515

62,320

76,482

Total operating expenses

164,101

224,080

479,386

635,716

Operating loss

(20,605)

(49,740)

(62,558)

(141,882)

   Financial expenses, net

1,242

(7,298)

(1,068)

(9,492)

   Other income (expenses)

117

25

149

84

Loss before taxes on income

(19,246)

(57,013)

(63,477)

(151,290)

   Taxes on income

(1,879)

(171)

1,364

2,441

Net loss

$         (17,367)

$              (56,842)

$       (64,841)

$     (153,731)

Basic and diluted net loss per share 

$              (0.34)

$                   (1.03)

$            (1.29)

$            (2.85)

Basic and diluted weighted-average shares used to compute net loss per share 

50,862,253

55,356,961

50,232,546

53,963,584

 

Wix.com Ltd.

CONDENSED CONSOLIDATED BALANCE SHEET

(In thousands)

Period ended

December 31,

September 30,

2019

2020


Assets

(audited)

(unaudited)

Current Assets:

Cash and cash equivalents

$         268,103

$         158,456

Short term deposits

294,096

540,069

Restricted cash and deposit

1,149

1,135

Marketable securities

164,301

299,743

Trade receivables 

16,987

23,159

Prepaid expenses and other current assets

19,211

57,481

 Total current assets

763,847

1,080,043

Long Term Assets:

Property and equipment, net

31,706

35,028

Marketable securities

177,298

540,047

Prepaid expenses and other long-term assets 

9,926

13,290

Intangible assets and goodwill, net

37,641

44,135

Operating lease assets

79,249

82,582

 Total long-term assets

335,820

715,082

 Total assets

$      1,099,667

$      1,795,125


Liabilities and Shareholder’s Equity

Current Liabilities:

Trade payables

$            37,687

$            70,346

Employees and payroll accruals

41,938

74,642

Deferred revenues

289,148

359,761

Accrued expenses and other current liabilities

56,464

68,699

Operating lease liabilities

18,949

19,111

Total current liabilities

444,186

592,559

Long term deferred revenues

21,969

40,780

Long term deferred tax liability

1,585

693

Convertible senior notes

358,715

823,029

Long term loan

1,219

1,219

Long term operating lease liabilities

64,244

69,348

Total long term liabilities

447,732

935,069

 Total liabilities

891,918

1,527,628

Shareholders’  Equity

   Ordinary shares

94

106

   Additional paid-in capital

611,083

817,006

   Other comprehensive loss

1,357

8,901

   Accumulated deficit

(404,785)

(558,516)

Total shareholders’ equity

207,749

267,497

Total liabilities and shareholders’ equity

$      1,099,667

$      1,795,125

 

Wix.com Ltd.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2019

2020

2019

2020

(unaudited)

(unaudited)

OPERATING ACTIVITIES:

Net loss 

$         (17,367)

$         (56,842)

$  (64,841)

$ (153,731)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation 

3,194

3,712

8,779

10,821

Amortization

733

826

2,203

1,958

Share based compensation expenses

28,392

38,922

80,864

104,607

Amortization of debt discount and debt issuance costs

5,274

7,594

15,585

18,543

Decrease in accrued interest and exchange rate on short term and long term deposits

137

(36)

731

26

Amortization of premium and discount and accrued interest on marketable securities, net

(140)

1,222

(99)

1,939

Deferred income taxes, net

(346)

(1,696)

187

(3,417)

Changes in operating lease right-of-use assets

3,907

13,353

Changes in operating lease liabilities

(3,377)

(13,194)

Decrease (increase) in trade receivables

2,029

(4,329)

(2,503)

(5,946)

Increase in prepaid expenses and other current and long-term assets

(1,683)

(7,183)

(12,824)

(28,788)

Increase (decrease) in trade payables

2,278

(3,331)

3,606

31,643

Increase in employees and payroll accruals

109

14,014

12,344

37,708

Increase in short term and long term deferred revenues

9,069

26,761

49,302

89,424

Increase in accrued expenses and other current liabilities

4,394

4,350

14,993

14,553

Net cash provided by operating activities

36,073

24,514

108,327

119,499

INVESTING ACTIVITIES:

   Proceeds from short-term deposits and restricted deposits

164,000

175,000

245,775

201,225

   Investment in short-term deposits and restricted deposits

(175,000)

(309,210)

(203,100)

(447,210)

   Investment in marketable securities

(127,967)

(468,473)

(264,583)

(698,641)

   Proceeds from marketable securities

32,246

45,104

61,302

200,015

   Purchase of property and equipment

(6,712)

(4,928)

(17,777)

(13,135)

   Capitalization of software development costs

(134)

(206)

(523)

(338)

   Investment in other short and long-term assets

(700)

(5,643)

   Payment for Businesses acquired

(6,626)

   Purchases of investments in privately-held companies

(262)

(262)

(785)

Net cash used in investing activities

(113,829)

(562,713)

(179,868)

(771,138)

FINANCING ACTIVITIES:

   Proceeds from exercise of options and ESPP shares

9,452

9,418

23,642

28,705

   Proceeds from issuance of convertible senior notes

575,000

575,000

   Payments of debt issuance costs

(15,713)

(15,713)

   Purchase of capped call

(46,000)

(46,000)

   Net cash provided by financing activities

9,452

522,705

23,642

541,992

INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

(68,304)

(15,494)

(47,899)

(109,647)

CASH AND CASH EQUIVALENTS—Beginning of period

351,462

173,950

331,057

268,103

CASH AND CASH EQUIVALENTS—End of period

$         283,158

$         158,456

$  283,158

$   158,456

 

Wix.com Ltd.

KEY PERFORMANCE METRICS

(In thousands)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2019

2020

2019

2020

(unaudited)

(unaudited)

Creative Subscriptions

164,761

202,996

473,137

569,711

Business Solutions

32,030

51,184

83,363

136,515


Total Revenue

$       196,791

$           254,180

$     556,500

$     706,226

Creative Subscriptions

173,571

228,327

520,958

654,820

Business Solutions

32,289

52,614

84,844

140,830


Total Collections

$       205,860

$           280,941

$     605,802

$     795,650

Free Cash Flow

$          29,227

$             19,380

$        90,027

$     106,026

Creative Subscriptions ARR

$       680,377

$           840,512

$     680,377

$     840,512

Number of registered users at period end (*)

159,543

189,390

159,543

189,390

Number of premium subscriptions at period end (*)

4,410

5,309

4,410

5,309

(*) Excludes users and subscriptions of DeviantArt

 

Wix.com Ltd.

RECONCILIATION OF REVENUES TO COLLECTIONS

(In thousands)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2019

2020

2019

2020

(unaudited)

(unaudited)

Revenues

$       196,791

$           254,180

$     556,500

$     706,226

Change in deferred revenues

9,069

26,761

49,302

89,424

Collections

$       205,860

$           280,941

$     605,802

$     795,650

Three Months Ended

Nine Months Ended

September 30,

September 30,

2019

2020

2019

2020

(unaudited)

(unaudited)

Creative Subscriptions Revenue

$       164,761

$           202,996

$     473,137

$     569,711

Change in deferred revenues

8,810

25,331

47,821

85,109

Creative Subscriptions Collections

$       173,571

$           228,327

$     520,958

$     654,820

Three Months Ended

Nine Months Ended

September 30,

September 30,

2019

2020

2019

2020

(unaudited)

(unaudited)

Business Solutions Revenue

$          32,030

$             51,184

$        83,363

$     136,515

Change in deferred revenues

259

1,430

1,481

4,315

Business Solutions Collections

$          32,289

$             52,614

$        84,844

$     140,830

 

Wix.com Ltd.

TOTAL ADJUSTMENTS GAAP TO NON-GAAP

(In thousands)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2019

2020

2019

2020

(1) Share based compensation expenses:

(unaudited)

(unaudited)

Cost of revenues

$            1,525

$                2,455

$          4,272

$          5,955

Research and development

14,886

20,312

41,261

54,713

Selling and marketing

4,590

6,108

13,844

16,071

General and administrative

7,391

10,047

21,487

27,868

Total share based compensation expenses

28,392

38,922

80,864

104,607

(2) Amortization

733

826

2,203

1,958

(3) Acquisition related expenses

564

1,489

617

4,125

(4) Amortization of debt discount and debt issuance costs

5,274

7,594

15,585

18,543

(5) Sales tax accrual and other G&A expenses (income)

3,174

3,174

1,489

(6) Non-operating foreign exchange expenses (income)

56

(5)

1,648

427

Total adjustments of GAAP to Non GAAP

$          38,193

$             48,826

$     104,091

$     131,149

 

Wix.com Ltd.

RECONCILIATION OF GAAP TO NON-GAAP GROSS PROFIT

(In thousands)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2019

2020

2019

2020

(unaudited)

(unaudited)

Gross Profit

$       143,496

$           174,340

$     416,828

$     493,834

Share based compensation expenses

1,525

2,455

4,272

5,955

Acquisition related expenses

200

505

Amortization 

142

226

425

226

Non GAAP Gross Profit 

145,163

177,221

421,525

500,520

Non GAAP Gross margin

74%

70%

76%

71%

Three Months Ended

Nine Months Ended

September 30,

September 30,

2019

2020

2019

2020

(unaudited)

(unaudited)

Gross Profit – Creative Subscriptions

$       133,219

$           159,635

$     385,652

$     452,450

Share based compensation expenses

1,285

1,947

3,660

4,754

Non GAAP Gross Profit – Creative Subscriptions

134,504

161,582

389,312

457,204

Non GAAP Gross margin – Creative Subscriptions

82%

80%

82%

80%

Three Months Ended

Nine Months Ended

September 30,

September 30,

2019

2020

2019

2020

(unaudited)

(unaudited)

Gross Profit – Business Solutions

$          10,277

$             14,705

$        31,176

$        41,384

Share based compensation expenses

240

508

612

1,201

Acquisition related expenses

200

505

Amortization 

142

226

425

226

Non GAAP Gross Profit – Business Solutions

10,659

15,639

32,213

43,316

Non GAAP Gross margin – Business Solutions

33%

31%

39%

32%

 

Wix.com Ltd.

RECONCILIATION OF OPERATING LOSS TO NON-GAAP OPERATING LOSS

(In thousands)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2019

2020

2019

2020

(unaudited)

(unaudited)

Operating loss

$       (20,605)

$           (49,740)

$     (62,558)

$   (141,882)

Adjustments:

  Share based compensation expenses

28,392

38,922

80,864

104,607

  Amortization 

733

826

2,203

1,958

  Sales tax accrual and other G&A expenses (income)

3,174

3,174

1,489

  Acquisition related expenses

564

1,489

617

4,125

Total adjustments

$          32,863

$             41,237

$        86,858

$     112,179

Non GAAP operating income (loss)

$          12,258

$             (8,503)

$        24,300

$     (29,703)

Wix.com Ltd.

RECONCILIATION OF NET LOSS TO NON-GAAP NET INCOME (LOSS) AND NON-GAAP NET INCOME (LOSS) PER SHARE

(In thousands, except  per share data)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2019

2020

2019

2020

(unaudited)

(unaudited)

Net loss

$       (17,367)

$           (56,842)

$     (64,841)

$   (153,731)

Share based compensation expense and other Non GAAP adjustments

38,193

48,826

104,091

131,149

Non-GAAP net income (loss)

$          20,826

$             (8,016)

$        39,250

$     (22,582)

Basic  Non GAAP net income (loss) per share

$              0.41

$                (0.14)

$            0.78

$          (0.42)

Weighted average shares used in computing basic Non GAAP net income (loss) per share

50,862,253

55,356,961

50,232,546

53,963,584

 

Wix.com Ltd.

RECONCILIATION OF NET CASH PROVIDED BY OPERATING ACTIVITIES TO FREE CASH FLOW

(In thousands)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2019

2020

2019

2020

(unaudited)

(unaudited)

Net cash provided by operating activities

$          36,073

$             24,514

$     108,327

$     119,499

Capital expenditures, net

(6,846)

(5,134)

(18,300)

(13,473)

Free Cash Flow

$          29,227

$             19,380

$        90,027

$     106,026

Capex related to future Wix HQ office build-out

779

1,670

Free Cash Flow, excluding capex related to future Wix HQ office build-out

$          29,227

$             20,159

$        90,027

$     107,696

 

Wix.com Ltd.

RECONCILIATION OF BASIC WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING AND THE DILUTED WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING 

Three Months Ended

Nine Months Ended

September 30,

September 30,

2019

2020

2019

2020

(unaudited)

(unaudited)

Basic and diluted weighted average number of shares outstanding 

50,862,253

55,356,961

50,232,546

53,963,584

The following items have been excluded from the diluted weighted average number of shares
outstanding because they are anti-dilutive:

Stock options

7,571,765

4,741,271

7,571,765

4,741,271

Restricted share units

2,231,470

2,109,920

2,231,470

2,109,920

 Convertible Notes (if-converted)

3,104,251

4,428,999

3,104,251

4,428,999

63,769,739

66,637,151

63,140,032

65,243,774

 

Wix.com Ltd.

RECONCILIATION OF PROJECTED REVENUES TO PROJECTED COLLECTIONS

(In thousands)

Three Months Ended

Year Ended

December 31, 2020

December 31, 2020

Low

High

Low

High

Projected revenues

266,000

271,000

972,000

977,000

Projected change in deferred revenues

29,000

34,000

118,000

123,000

Projected Collections

$       295,000

$           305,000

$  1,090,000

$  1,100,000

 

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/wix-reports-third-quarter-2020-results-301171574.html

SOURCE Wix.com Ltd.